Xiaodong Wang Sells 41,760 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock

Beigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 41,760 shares of Beigene stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $242.66, for a total transaction of $10,133,481.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, March 18th, Xiaodong Wang sold 41,760 shares of Beigene stock. The shares were sold at an average price of $261.28, for a total value of $10,911,052.80.
• On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68.

Beigene Price Performance

ONC stock traded up $2.84 during midday trading on Friday, reaching $230.98. The company had a trading volume of 519,865 shares, compared to its average volume of 491,582. Beigene, Ltd. has a 1-year low of $126.97 and a 1-year high of $287.88. The company's 50 day simple moving average is $246.17. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The stock has a market capitalization of $22.79 billion, a P/E ratio of -28.03, a price-to-earnings-growth ratio of 7.73 and a beta of 0.49.

Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). The firm had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. As a group, research analysts anticipate that Beigene, Ltd. will post -5.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Bank of America upgraded shares of Beigene from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. JMP Securities set a $348.00 price objective on Beigene in a report on Friday, February 28th. Sanford C. Bernstein set a $259.00 target price on Beigene in a report on Thursday, March 13th. Macquarie upped their price target on shares of Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Finally, Guggenheim reiterated a "buy" rating on shares of Beigene in a research note on Wednesday.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.